nach oben

Rheumatology International

Erschienen in:

23.07.2021 | Systematic Review

Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysis

verfasst von: Durga Prasanna Misra, Upendra Rathore, Pallavi Patro, Vikas Agarwal, Aman Sharma

Erschienen in: Rheumatology International | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

We evaluated clinical response, normalization of inflammatory markers, angiographic stabilization (primary outcomes), relapses and adverse events (secondary outcomes) in Takayasu arteritis (TAK) patients following corticosteroid monotherapy. MEDLINE, EMBASE, Web of Science, Scopus, Pubmed Central, Cochrane library, clinical trial databases and major international Rheumatology conferences were searched for studies reporting outcomes in TAK following corticosteroid monotherapy (without language/date restrictions). Risk ratios were calculated for controlled studies. Proportions were pooled for uncontrolled studies. Heterogeneity was assessed using I² statistic. Quality assessment of individual studies utilized the Newcastle–Ottawa scale. GRADE methodology ascertained certainty of individual outcomes across studies. Twenty-eight observational studies (1098 TAK) were identified. Twenty-three uncontrolled studies (580 TAK) were synthesized in meta-analysis. Clinical response was observed in 60% (95% CI 45–74%, 19 studies), normalization of inflammatory markers in 84% (95% CI 54–100%, 4 studies) and angiographic stabilization in 28% (95% CI 6–57%, 4 studies). Relapses occurred in 66% (95% CI 18–99%, 4 studies). Adverse events were reported in 51% (95% CI 2–99%, 4 studies). All pooled estimates had considerable heterogeneity, unexplained by subgroup analyses (time period, geographic location or number of patients). Two studies reported lesser restenosis following vascular surgery and fewer relapses when corticosteroids were combined with immunosuppressants compared with corticosteroid monotherapy. All outcomes had very low certainty. While corticosteroid monotherapy induces clinical response in most TAK patients, angiographic stabilization is observed in fewer than one-third. Most patients relapse following corticosteroid withdrawal. Preliminary evidence supports up-front addition of immunosuppressants to retard angiographic progression and reduce relapses (PROSPERO identifier CRD42021242910).

Nur mit Berechtigung zugänglich

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715CrossRef

Keser G, Direskeneli H, Aksu K (2014) Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford) 53:793–801. https://doi.org/10.1093/rheumatology/ket320CrossRefPubMed

Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68. https://doi.org/10.1111/1756-185x.13285CrossRefPubMed

Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev 11:61–67. https://doi.org/10.1016/j.autrev.2011.08.001CrossRefPubMed

Misra DP, Chaurasia S, Misra R (2016) Increased circulating Th17 cells, serum IL-17A, and IL-23 in Takayasu arteritis. Autoimmun Dis. https://doi.org/10.1155/2016/7841718CrossRef

Castillo-Martínez D, Amezcua-Castillo LM, Granados J, Pineda C, Amezcua-Guerra LM (2020) Is Takayasu arteritis the result of a Mycobacterium tuberculosis infection? The use of TNF inhibitors may be the proof-of-concept to demonstrate that this association is epiphenomenal. Clin Rheumatol 39:2003–2009. https://doi.org/10.1007/s10067-020-05045-zCrossRefPubMed

Misra DP, Misra R (2015) Assessment of disease activity in Takayasu’s arteritis. Indian J Rheumatol 10:S43–S47. https://doi.org/10.1016/j.injr.2015.08.006CrossRef

Misra DP, Sharma A, Kadhiravan T, Negi VS (2017) A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 16:179–191. https://doi.org/10.1016/j.autrev.2016.12.009CrossRefPubMed

Misra DP, Agarwal V (2020) The perennial search for alternatives to corticosteroids in rheumatology: is there light at the end of the tunnel? Clin Rheumatol 39:2845–2848. https://doi.org/10.1007/s10067-020-05357-0CrossRefPubMed

10.

Dua A, Das P, Ravindran V (2019) Glucocorticoids: a review of its adverse effects including bone loss. Indian J Rheumatol 14:90–98. https://doi.org/10.4103/0973-3698.272158CrossRef

11.

Misra DP, Rathore U, Patro P, Agarwal V, Sharma A (2021) Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05743-2CrossRefPubMedPubMedCentral

12.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. John Wiley & Sons, Chichester

13.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:1000097–1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRef

14.

Rethlefsen ML, Kirtley S, Waffenschmidt S et al (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 10:39. https://doi.org/10.1186/s13643-020-01542-zCrossRefPubMedPubMedCentral

15.

Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008–2012. https://doi.org/10.1001/jama.283.15.2008CrossRef

16.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

17.

Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134. https://doi.org/10.1002/art.1780330811CrossRefPubMed

18.

Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol 12:964–972. https://doi.org/10.1016/0735-1097(88)90462-7CrossRefPubMed

19.

Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141-147CrossRefPubMed

20.

Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806. https://doi.org/10.1136/ard.2009.116657CrossRefPubMed

21.

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898CrossRefPubMed

22.

Newcastle-Ottawa scale. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed on 16 Apr 2021

23.

Li L, Liu C, Cheng L, Yan S, Chen H, Li Y (2021) Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol 40:819–832. https://doi.org/10.1007/s10067-020-05291-1CrossRefPubMed

24.

Lin L, Chu H (2018) Quantifying publication bias in meta-analysis. Biometrics 74:785–794. https://doi.org/10.1111/biom.12817CrossRefPubMed

25.

Misra DP, Agarwal V (2018) Systematic reviews: challenges for their justification, related comprehensive searches, and implications. J Korean Med Sci 33:9. https://doi.org/10.3346/jkms.2018.33.e92CrossRef

26.

Online calculator for pooling variances. https://home.ubalt.edu/ntsbarsh/business-stat/otherapplets/Pooled.htm. Accessed 20 Apr 2021

27.

Practical meta-analysis effect size calculator. Available at https://campbellcollaboration.org/escalc/html/EffectSizeCalculator-SMD1.php. Accessed 23 Jul 2021

28.

Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72:39. https://doi.org/10.1186/2049-3258-72-39CrossRefPubMedPubMedCentral

29.

Brunner J, Feldman BM, Tyrrell PN et al (2010) Takayasu arteritis in children and adolescents. Rheumatology (Oxford) 49:1806–1814. https://doi.org/10.1093/rheumatology/keq167CrossRef

30.

Misra DP, Aggarwal A, Lawrence A, Agarwal V, Misra R (2015) Pediatric-onset Takayasu’s arteritis: clinical features and short-term outcome. Rheumatol Int 35:1701–1706. https://doi.org/10.1007/s00296-015-3272-7CrossRefPubMed

31.

GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2020 (developed by Evidence Prime, Inc.). Available from gradepro.org.

32.

Nakao K, Ikeda M, Kimata S, Niitani H, Niyahara M (1967) Takayasu’s arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation 35:1141–1155. https://doi.org/10.1161/01.cir.35.6.1141CrossRefPubMed

33.

Fraga A, Mintz G, Valle L, Flores-Izquierdo G (1972) Takayasu’s arteritis: frequency of systemic manifestations (study of 22 patients) and favorable response to maintenance steroid therapy with adrenocorticosteroids (12 patients). Arthritis Rheum 15:617–624. https://doi.org/10.1002/art.1780150608CrossRefPubMed

34.

Morooka S, Ito I, Yamaguchi H, Takeda T, Saito Y (1972) Follow-up observation of aortitis syndrome. Jpn Heart J 13:201–213. https://doi.org/10.1536/ihj.13.201CrossRefPubMed

35.

Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE (1977) Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J 93:94–103. https://doi.org/10.1016/s0002-8703(77)80178-6CrossRefPubMed

36.

Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG (1985) Takayasu arteritis: a study of 32 north American patients. Medicine (Baltimore) 64:89–99. https://doi.org/10.1097/00005792-198503000-00002CrossRef

37.

Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103:121–126. https://doi.org/10.7326/0003-4819-103-1-121CrossRef

38.

Weaver FA, Yellin AE, Campen DH et al (1990) Surgical procedures in the management of Takayasu’s arteritis. J Vasc Surg 12:429–439. https://doi.org/10.1016/0741-5214(90)90045-CCrossRef

39.

Ishikawa K (1991) Effects of prednisolone therapy on arterial angiographic features in Takayasu’s disease. Am J Cardiol 68:410–413. https://doi.org/10.1016/0002-9149(91)90845-CCrossRef

40.

Zheng D, Fan D, Liu L (1992) Takayasu arteritis in China: a report of 530 cases. Heart Vessels Suppl 7:32–36CrossRefPubMed

41.

Kerr GS, Hallahan CW, Giordano J et al (1994) Takayasu arteritis. Ann Intern Med 120:919–929. https://doi.org/10.7326/0003-4819-120-11-199406010-00004CrossRefPubMed

42.

Jain S, Kumari S, Ganguly NK, Sharma BK (1996) Current status of Takayasu arteritis in India. Int J Cardiol 54:S111–S116. https://doi.org/10.1016/S0167-5273(96)88780-8CrossRefPubMed

43.

Lambert M, Hachulla E, Hatron PY et al (1998) Takayasu’s arteritis: vascular investigations and therapeutic management. Experience with 16 patients. Rev Med Interne 19:878–884CrossRefPubMed

44.

Sato EI, Lima DN, Santo BE, Hata F (2000) Takayasu arteritis. Treatment and prognosis in a university center in Brazil. Int J Cardiol 75(Suppl 1):163–166CrossRef

45.

Paul JF, Fiessinger JN, Sapoval M et al (2001) Follow-up electron beam CT for the management of early phase Takayasu arteritis. J Comput Assist Tomogr 25:924–931. https://doi.org/10.1097/00004728-200111000-00015CrossRefPubMed

46.

El Asri A, Tazi-Mezalek Z, Aouni M et al (2002) Takayasu’s arteritis in Morroco. A study of 47 cases. Rev Med Interne 23:9–20. https://doi.org/10.1016/s0248-8663(01)00510-0CrossRefPubMed

47.

Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH (2006) Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu’s arteritis. Rheumatology (Oxford) 45:600–605. https://doi.org/10.1093/rheumatology/kei245CrossRefPubMed

48.

Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2007) Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56:1000–1009. https://doi.org/10.1002/art.22404CrossRefPubMed

49.

Petrovic-Rackov L, Pejnovic N, Jevtic M, Damjanov N (2009) Longitudinal study of 16 patients with Takayasu’s arteritis: clinical features and therapeutic management. Clin Rheumatol 28:179–185. https://doi.org/10.1007/s10067-008-1009-7CrossRefPubMed

50.

Arnaud L, Haroche J, Limal N et al (2010) Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine 89:1–17. https://doi.org/10.1097/MD.0b013e3181cba0a3CrossRefPubMed

51.

Cong X-L, Dai S-M, Feng X et al (2010) Takayasu’s arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 29:973–981. https://doi.org/10.1007/s10067-010-1496-1CrossRefPubMed

52.

Jaafoura NG, Khalifa M, Rezgui A et al (2010) Takayasu’s disease in central Tunisia: 27 cases. J Mal Vasc 35:4–11. https://doi.org/10.1016/j.jmv.2009.09.002CrossRef

53.

Nunes G, Neves FS, Melo FM, de Castro GRW, Zimmermann AF, Pereira IA (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:295–298. https://doi.org/10.1590/s0482-50042010000300009CrossRef

54.

Ohigashi H, Haraguchi G, Konishi M et al (2012) Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 76:1004–1011. https://doi.org/10.1253/circj.CJ-11-1108CrossRefPubMed

55.

Yang L, Zhang H, Jiang X et al (2015) Clinical features and outcomes of Takayasu arteritis with neurological symptoms in China: a retrospective study. J Rheumatol 42:1846–1852. https://doi.org/10.3899/jrheum.150097CrossRefPubMed

56.

Gudbrandsson B, Molberg PO (2017) TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 19:99. https://doi.org/10.1186/s13075-017-1316-yCrossRefPubMedPubMedCentral

57.

Ohigashi H, Tamura N, Ebana Y et al (2017) Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 69:774–778. https://doi.org/10.1016/j.jjcc.2016.07.009CrossRefPubMed

58.

Peng Y-F, Guo J, Deng Y-B (2017) The role of mean platelet volume in patients with Takayasu arteritis. Ann Clin Biochem 54:273–278. https://doi.org/10.1177/0004563216658312CrossRefPubMed

59.

Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H (2020) Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol 47:255–263. https://doi.org/10.3899/jrheum.181219CrossRefPubMed

60.

Hoffman GS (1996) Takayasu arteritis: lessons from the American National Institutes of Health Experience. Int J Cardiol 54:S99–S102. https://doi.org/10.1016/s0167-5273(96)88778-xCrossRefPubMed

61.

Maz M, Chung SA, Abril A et al (2021) 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. https://doi.org/10.1002/art.41774CrossRefPubMed

62.

IntHout J, Ioannidis JPA, Borm GF, Goeman JJ (2015) Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol 68:860–869. https://doi.org/10.1016/j.jclinepi.2015.03.017CrossRefPubMed

63.

Misra DP, Naidu G, Agarwal V, Sharma A (2019) Vasculitis research: current trends and future perspectives. Int J Rheum Dis 22(Suppl 1):10–20. https://doi.org/10.1111/1756-185x.13370CrossRefPubMed

64.

Barra L, Kanji T, Malette J, Pagnoux C (2018) Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev 17:175–187. https://doi.org/10.1016/j.autrev.2017.11.021CrossRefPubMed

65.

Incerti E, Tombetti E, Fallanca F et al (2017) (18)F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu’s arteritis. Eur J Nucl Med Mol Imaging 44:1109–1118. https://doi.org/10.1007/s00259-017-3639-yCrossRefPubMed

66.

Wen X, Hou R, Xu K et al (2021) Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: a systematic review and meta-analysis. PLoS ONE 16:e0245612. https://doi.org/10.1371/journal.pone.0245612CrossRefPubMedPubMedCentral

67.

Goel R, Nair A, Kabeerdoss J et al (2018) Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study. Rheumatol Int 38:623–630. https://doi.org/10.1007/s00296-017-3881-4CrossRefPubMed

68.

Saadoun D, Garrido M, Comarmond C et al (2015) Th1 and Th17 cytokines drive inflammation in takayasu arteritis. Arthritis Rheumatol 67:1353–1360. https://doi.org/10.1002/art.39037CrossRefPubMed

69.

Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121:906–915. https://doi.org/10.1161/circulationaha.109.872903CrossRefPubMedPubMedCentral

70.

Ramesh R, Kozhaya L, McKevitt K et al (2014) Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 211:89–104. https://doi.org/10.1084/jem.20130301CrossRefPubMedPubMedCentral

71.

Kansal A, Tripathi D, Rai MK, Agarwal V (2016) Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. Clin Rheumatol 35:341–349. https://doi.org/10.1007/s10067-015-3079-7CrossRefPubMed

72.

Prasad S, Tripathi D, Rai MK, Aggarwal S, Mittal B, Agarwal V (2014) Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate. Int J Rheum Dis 17:878–886. https://doi.org/10.1111/1756-185x.12362CrossRefPubMed

73.

Osborne SF, Jordan K (2004) Spontaneous regression of optic disc neovascularization in Takayasu arteritis. Eye 18:86–88. https://doi.org/10.1038/sj.eye.6700508CrossRefPubMed

74.

Palmowski A, Buttgereit F (2020) Reducing the toxicity of long-term glucocorticoid treatment in large vessel vasculitis. Curr Rheumatol Rep 22:85. https://doi.org/10.1007/s11926-020-00961-0CrossRefPubMedPubMedCentral

Titel: Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysis
verfasst von: Durga Prasanna Misra
Upendra Rathore
Pallavi Patro
Vikas Agarwal
Aman Sharma
Publikationsdatum: 23.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 10/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04958-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Correction to: Anti-Sjögren’s-syndrome-related antigen A autoantibodies (Anti-SSA antibody) and meningoencephalitis: Sjögren’s syndrome waiting to be unveiled? A case series and review of literature

Telerheumatology and its interplay with patient-initiated care

Aseptic meningitis in rheumatoid arthritis after anti-TNF administration: a case-based literature review

Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review

Assessment of the responsiveness of four scales in geriatric patients with chronic neck pain